OREANDA-NEWS. Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the second quarter ended June 30, 2016 and provided an update on the Company's corporate and clinical development activities.

“Encouraged by the MAESTRO data presented recently at ASCO that demonstrated meaningful improvement in overall survival in the subgroup of patients from Japan and South Korea, we are pursuing a registration strategy for Japan,” said Barry Selick, Ph.D., Chief Executive Officer of Threshold. “We have also been encouraged by the translational data evaluating the role of hypoxia in mediating treatment resistance to cancer immunotherapy conducted by collaborators at the MD Anderson Cancer Center and to initiating a clinical trial evaluating evofosfamide in combination with checkpoint blockade.”

Recent Highlights
Evofosfamide – The Company’s lead product candidate is an investigational hypoxia-activated prodrug that is designed to be activated under tumor hypoxic conditions, a hallmark of many cancers.

  • Additional data analyses from the MAESTRO Phase 3 trial, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting recently, reported on the subgroup of 123 Asian patients enrolled at Japanese and South Korean sites in which the risk of death was reduced by 48 percent for patients on the treatment arm compared to patients on the control arm with an associated stratified hazard ratio of 0.52 (95% CI: 0.32 - 0.85);
  • The Company is evaluating the feasibility of submitting a New Drug Application (NDA) for registration with the Pharmaceuticals and Medical Devices Agency, or PMDA, in Japan based on the results seen in the Japanese sub-population;
  • Clinical development collaborations investigating evofosfamide in patients with pancreatic neuroendocrine tumors (pNET), recurrent glioblastoma (GBM) and hepatocellular carcinoma (HCC) remain ongoing; and
  • A recent presentation by one of the Company’s collaborators from the MD Anderson Cancer Center highlighted the promise of evofosfamide in combination with “checkpoint antibodies” to improve the efficacy of this class of potent anti-cancer therapies. A clinical trial evaluating evofosfamide plus ipilimumab to treat a variety of solid tumors is planned.

Tarloxotinib – Beyond the evofosfamide program, the Company is pursuing the Phase 2 proof of concept studies with tarloxotinib, a hypoxia-activated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which is designed to selectively release an irreversible EGFR-TKI in hypoxic tumors.

  • Investigations continue in two proof-of-concept, Phase 2 clinical trials in patients with advanced non-small cell lung cancer (NSCLC) and patients with metastatic squamous cell carcinoma of the head and neck and skin; the designs of both trials necessitate a minimum response rate for study continuation. When the specified target numbers of patients have been assessed, the Company plans to report the preliminary results; this is estimated to occur in the third quarter of 2016.

Second Quarter 2016 Financial Results

  • Cash, cash equivalents and marketable securities totaled $33.6 million at June 30, 2016 compared to $38.0 million at March 31, 2016; the net decrease of $4.4 million was a result of operating cash requirements for the quarter ended June 30, 2016. With the previously announced decision to cease joint development of evofosfamide under the Company’s former collaboration with Merck KGaA and the workforce reduction, the Company continues to expect its operating cash requirements to be lower for the second half of fiscal year 2016 compared to the first half of 2016.
  • No revenue was recognized in the second quarter ended June 30, 2016 compared to $3.7 million for the same period of 2015. Revenue for the quarter ended June 30, 2015 related to the amortization of the aggregate of $110 million in upfront and milestone payments received from the Company’s former collaboration with Merck KGaA, Darmstadt, Germany. The revenue from the upfront payment and milestone payments received under the agreement were previously being amortized over the relevant performance period, rather than being immediately recognized when the upfront payment and milestones were earned or received. As a result of Merck KGaA, Darmstadt, Germany's and the Company’s decision to cease further joint development of evofosfamide in December 2015, the Company immediately recognized all of the remaining deferred revenue into revenue during the quarter ending December 31, 2015.  Also as a result of the termination of the agreement, the Company is no longer eligible to receive any further milestone payments from Merck KGaA, Darmstadt, Germany.
     
  • Research and development expenses were $4.0 million for the second quarter ended June 30, 2016, compared to $10.1 million for the same period in 2015. The decrease in research and development expenses, net of reimbursement for Merck KGaA, Darmstadt, Germany’s 70 percent share of total eligible collaboration expenses for evofosfamide, was due primarily to a $3.6 million decrease in employee related expenses, including a $0.9 million decrease in non-cash stock-based compensation expense and a $2.5 million decrease in clinical development expenses and consulting expenses. The Company expects research and development expenses to continue to decline in 2016 as result of the decision to cease further joint development of evofosfamide under the Company’s former collaboration with Merck KGaA and the workforce reduction.
  • General and administrative expenses were $1.9 million for the second quarter ended June 30, 2016 compared to $2.5 million for the same period in 2015. The decrease in general and administrative expenses was due primarily to a $0.5 million decrease in employee related expenses and a $0.1 million decrease in consulting expenses.
  • Non-cash stock-based compensation expense included in total operating expenses was $0.8 million for the second quarter of 2016 compared to $1.9 million for same period in 2015. The decrease in stock-based compensation expense was due to the amortization of a smaller number of options with lower fair values.
  • Net loss for the second quarter of 2016 was $6.9 million compared to $8.3 million for the same period in 2015. Included in the net loss for the second quarter of 2016 was an operating loss of $5.9 million and non-cash expense of $1.0 million compared to an operating loss of $8.9 million and non-cash income of $0.6 million for the second quarter of 2015. The non-cash income or expense is related to changes in the fair value of the Company’s outstanding and exercised warrants that was classified as other income (expense).

About Evofosfamide
Evofosfamide (previously known as TH-302) is an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood vessel supply. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic. On December 6, 2015, the Company announced the outcomes of two Phase 3 studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide stating that neither study met its primary endpoint. 

About Tarloxotinib Bromide
Tarloxotinib bromide (the proposed International Nonproprietary Name, previously known as TH-4000), or "tarloxotinib", is a prodrug designed to selectively release a covalent (irreversible) EGFR tyrosine kinase inhibitor under severe hypoxia, a feature of many solid tumors. Accordingly, tarloxotinib has the potential to effectively shut down aberrant EGFR signaling in a tumor-selective manner, thus potentially avoiding or reducing the systemic side effects associated with currently available EGFR tyrosine kinase inhibitors. Tarloxotinib is currently being evaluated in two Phase 2 proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer progressing on an EGFR tyrosine kinase inhibitor, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck or skin. Threshold licensed exclusive worldwide rights to tarloxotinib from the University of Auckland, New Zealand, in September 2014. 

About Threshold Pharmaceuticals
Threshold is a clinical-stage biopharmaceutical company focused on the discovery and development of drugs and diagnostic agents targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the Company’s website. 

 

 
THRESHOLD PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
         
         
  Three Months Ended   Six Months Ended
  June 30,   June 30,
    2016       2015       2016       2015  
               
               
Revenue $ -     $ 3,680     $ -     $ 7,361  
               
Operating expenses              
Research and development   4,016       10,141       10,021       20,821  
General and administrative   1,892       2,480       4,141       5,096  
Total Operating Expenses   5,908       12,621       14,162       25,917  
               
Loss from operations   (5,908 )     (8,941 )     (14,162 )     (18,556 )
               
Interest income (expense), net   40       39       72       72  
Other income (expense) (1)   (996 )     596       (626 )     (976 )
Net loss $    (6,864 )   $    (8,306 )   $    (14,716 )   $    (19,460 )
   
Net loss per common share  
Basic $    (0.10 )   $    (0.12 )   $    (0.21 )   $    (0.28 )
Diluted $    (0.10 )   $    (0.12 )   $    (0.21 )   $    (0.28 )
               
Weighted-average shares used in per common              
share calculation:              
Basic   71,511       71,334       71,500       69,046  
Diluted   71,511       72,815       71,500       69,046  
             
(1) Noncash income (expense) related to change in the fair value of the Company's outstanding and exercised
warrants, classified as other income (expense).
             
         
  THRESHOLD PHARMACEUTICALS, INC.
  CONDENSED CONSOLIDATED BALANCE SHEETS
  (in thousands)
         
         
    June 30, 
2016 
(unaudited)
  December 31, 
2015 
(1)
     
     
Assets      
         
Cash, cash equivalents and      
marketable securities $ 33,591     $   48,680    
Collaboration Receivable   921         1,891    
Prepaid expenses and other current assets   1,294         2,599    
Property and equipment, net   208         333    
Other assets   166         166    
Total assets $    36,180     $      53,669    
         
Liabilities and stockholders' equity      
         
Total current liabilities $ 5,789     $   10,828    
Long-term liabilities (2)   2,577         1,995    
Stockholders' equity (deficit)   27,814         40,846    
Total liabilities and stockholders' equity (deficit) $    36,180     $      53,669    
         
         
(1) Derived from audited financial statements
(2) Includes as of June 30, 2016 and December 31, 2015, $2.5 million and $1.9 million of warrant liability, respectively.